Effects of Δ9-tetrahydrocannabinol, (R)-methanandamide, SR 141716, and d-amphetamine before and during daily Δ9-tetrahydrocannabinol dosing

European Journal of Pharmacology

Volumn 398, Issue 2, 2000, Pages 251-258

  Lamb, Richard J ^a,b   Järbe, Torbjörn U C ^b,c   Makriyannis, Alexandros ^d   Lin, Sonyan ^d   Goutopoulos, Andreas ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c TEMPLE UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

9 Tetrahydrocannabinol; (R) Methanandamide; Amphetamine; Anandamide; Cross tolerance; Dependence; Operant behavior; Rat; SR 141716; Tolerance

Indexed keywords

DEXAMPHETAMINE; DRONABINOL; METHANANDAMIDE; RIMONABANT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CROSS TOLERANCE; DOSE RESPONSE; DRUG TOLERANCE; FOOD; INSTRUMENTAL CONDITIONING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT;

ANIMALS; ARACHIDONIC ACIDS; BEHAVIOR, ANIMAL; CONDITIONING, OPERANT; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG TOLERANCE; MALE; PIPERIDINES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 0343239120     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(00)00318-6     Document Type: Article

References (29)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1893.
2. 1 receptor antagonist SR 141716A, after Δ9-tetrahydrocannabinol withdrawal. Eur. J. Pharmacol. 387:2000;47-53.
3. Beardsley P.M., Balster R.L., Harris L.S. Dependence on tetrahydrocannabinol in Rhesus monkeys. J. Pharmacol. Exp. Ther. 239:1986;311-319.
4. Davis W.M., Borgen L.A. Tolerance development to the effect of Δ9-tetrahydrocannabinol on conditioned behavior: role of treatment interval and influence of microsomal metabolism. Arch. Int. Pharmacodyn. Ther. 213:1975;97-111.
5. Fride E. Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol. Brain Res. 697:1995;83-90.
6. Gellert V.F., Sparber S.B. A comparison of the effects of naloxone upon body weight loss and suppression of fixed-ratio operant behavior in morphine dependent rats. J. Pharmacol. Exp. Ther. 201:1977;44-54.
7. Hanus L., Gopher A., Almog S., Mechoulam R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem. 36:1993;3032-3034.
8. Huidobro F., Maggiolo C., Contreras E. Studies on morphine: I. Effects of nalorphine and levallorphan in mice implanted with pellets of morphine. Arch. Int. Pharmacodyn. Ther. 144:1963;196-205.
9. Järbe T.U.C., Lamb R.J., Makriyannis A., Lin S., Goutopoulos W. Δ9-THC training dose as a determinant for (R)-methanandamide generalization. Psychopharmacology. 140:1998;519-522.
10. Järbe T.U.C., Lamb R.J., Lin S., Makriyannis A. Δ9-THC training dose as a determinant for (R)-methanandamide generalization in rats: a systematic replication. Behav. Pharmacol. 11:2000;81-86.
11. Khanolkar A.D., Abadji V., Lin S., Hill W.A., Taha G., Abouzid K., Meng Z., Fan P., Makriyannis A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem. 39:1996;4515-4519.
12. Kosersky D.S., McMillan D.E., Harris L.S. Δ9-Tetrahydrocannabinol and 11-hydroxycannabinol: behavioral effects and tolerance development. J. Pharmacol. Exp. Ther. 189:1974;61-65.
13. Lamb R.J., Griffiths R.R. Precipitated and spontaneous withdrawal in baboons after chronic dosing with lorazepam and CGS 9896. Drug Alcohol Depend. 14:1984;11-17.
14. Lamb R.J., Griffiths R.R. Effects of repeated Ro 15-1788 administration in benzodiazepine-dependent baboons. Eur. J. Pharmacol. 110:1985;257-261.
15. Lamb R.J., Järbe T.U.C. Fluvoxamine and ethanol: behavioral interactions. Harris L.S. Problems of Drug Dependence 1996: Proceedings of the 58th Annual Scientific Meeting, The College on Problems of Drug Dependence. 1997;246 US Depeartment of Health and Human Services.
16. Lucki I., Kucharik R.F. Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam. Psychopharmacology. 102:1990;350-356.
17. Lukas S.E., Griffiths R.R. Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam. Science. 217:1982;1161-1163.
18. Mackie K., Devane W.A., Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol. Pharmacol. 44:1993;498-503.
19. McMillan D.E., Dewey W.L., Harris L.S. Characteristics of tetrahydrocannabinol tolerance. Ann. N. Y. Acad. Sci. 191:1971;83-99.
20. McMillan D.E., Hardwick W.C., Wells J.D. Effects of barbiturates in rats tolerant to Δ9-tetrahydrocannabinol. Arch. Int. Pharmacodyn. Ther. 264:1983;4-14.
21. Mechoulam R., Hanus L., Martin B.R. Search for endogenous ligands of the cannabinoid receptor. Biochem. Pharmacol. 48:1994;1537-1544.
22. Pertwee R.G., Griffin G. A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol. 272:1995;67-72.
23. Pertwee R.G., Stevenson L.A., Griffin G. Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol. 110:1993;1483-1490.
24. Takada K., Suzuki T., Hagen T., Cook J.M., Katz J.L. Behavioral effects of benzodiazepine antagonists in chlordiazepoxide tolerant and non-tolerant rats. Life Sci. 44:1989;289-299.
25. Tallarida R.J., Murray R.B. Manual of Pharmacologic Calculations with Computer Programs. 2nd edn. 1987;Springer-Verlag, New York.
26. Tsou K., Patrick S., Walker J.M. Physical withdrawal in rats tolerant to Δ9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur. J. Pharmacol. 280:1995;R13-15.
27. Welch S.P. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphin. Drug Alcohol Depend. 45:1997;39-45.
28. Welch S.P., Dunlow l.D., Patrick G.S., Razdan R.K. Characterization of anandamide- and fluroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J. Pharmacol. Exp. Ther. 273:1995;1235-1244.
29. Young A.M. Discriminative stimulus profiles of psychoactive drugs. Mello N. Advances in Substance Abuse. vol. 4:1991;139-203 Kingsley Press, London.